Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEWARK, Calif., March 13, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
-
NEWARK, Calif., March 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
-
NEWARK, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Rodney Young, Chief Financial Officer, will present an update on the Company's programs and...
-
NEWARK, Calif., Feb. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it will participate in the Qatar International Conference on Stem Cell Science and Policy, which is...
-
NEWARK, Calif., Feb. 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at...
-
NEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical...
-
NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of preclinical data demonstrating that its proprietary HuCNS-SC® cells (purified...
-
NEWARK, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem...
-
NEWARK, Calif., Dec. 22, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed its previously announced underwritten offering of an aggregate of 8,000,000 units and...
-
NEWARK, Calif., Dec. 16, 2011 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the pricing of an underwritten public offering of an aggregate of 8,000,000 units and 8,000,000 Series B...